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Cases were identified with a specific diagnosis of either Graves disease (ICD-9-CM code 242.0) or Hashimoto thyroiditis (ICD-9-CM code 245.2). Cases were defined as individuals with an inpatient ICD-9-CM diagnosis code in any diagnosis position or 2 or more first diagnosis-position outpatient codes separated by at least 7 days.
Because persons with Graves disease and active thyroiditis are not eligible to enlist in the US military, the first diagnosis code was considered the incidence date. We calculated directly standardized incidence of Graves disease and Hashimoto thyroiditis among race/ethnicities, standardized to (Table) . Compared with whites, the IRR for Graves disease was significantly elevated in black women (IRR, 1.92; 95% CI, 1.56-2.37) and men (IRR, 2.53; 95% CI, 2.01-3.18) and Asian/ Pacific Islander women (IRR, 1.78; 95% CI, 1.20-2.66) and men (IRR, 3.36; 95% CI, 2.57-4.40) ( Figure) . In contrast, Hashimoto thyroiditis incidence was highest in whites and lowest in black women (IRR, 0.33; 95% CI, 0.21-0.51) and men (IRR, 0.22; 95% CI, 0.11-0.47) and Asian/Pacific Islander women (IRR, 0.31; 95% CI, 0.17-0.56) and men (IRR, 0.23; 95% CI, 0.07-0.72) ( Figure) .
Discussion | To our knowledge, this is the first report to identify that Graves disease is more common in blacks and Asian/ Pacific Islanders compared with whites. In contrast, the relationship between Hashimoto thyroiditis and race is well known, 1,2 and is confirmed by our results.
The differences in incidence by race/ethnicity may be due to different environmental exposures, genetics, or a combination of both. Our results are not easily attributable to the strongest known environmental risk factor, cigarette smoking.
Smoking is associated with an increased risk for Graves disease and a decreased risk of Hashimoto thyroiditis. 4, 5 Whites have the highest smoking rates in the US military. 6 However, whites had higher rates of Hashimoto thyroiditis and lower rates of Graves disease. Our data set presumes accurate coding; it is possible that some cases of Hashimoto thyroiditis causing hypothyroidism were coded as unspecified-acquired hypothyroidism and not Hashimoto thyroiditis. The military population may also tend to have lower Hashimoto thyroiditis estimates because it is younger than the general population and has higher smoking prevalence.
Another potential limitation is the misclassification of prevalent cases as incident cases, although this is unlikely to be important because diagnosis during the teenage years is rare. We also cannot rule out military-specific exposures affecting the pattern of autoimmune thyroid disease, which could limit the generalizability of our findings. 
COMMENT & RESPONSE

Dopamine vs Nesiritide for Acute Heart Failure With Renal Dysfunction
To the Editor Dr Chen and colleagues 1 evaluated the role of low-dose dopamine and nesiritide as individual strategies in treating patients with acute decongested heart failure while attempting to preserve or improve renal function. The trial found no benefit from low-dose dopamine or nesiritide with standard diuretic therapy. Despite significant advances in understanding the pathophysiology of acute heart failure, contemporary therapies have failed to have an effect.
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The Renal Optimization Strategies Evaluation (ROSE) trial raises more questions than it answers. The trial included a fair proportion of patients with heart failure and preserved ejection fraction. In subgroup analyses, only patients with heart failure with reduced ejection fraction showed a suggestion of a response to low-dose nesiritide and dopamine. Heart failure with preserved and reduced ejection fraction are often treated as one entity in clinical practice and research.
Similar drugs are used for heart failure with reduced and preserved ejection fraction, with little to no success. Mechanistic, observational, and randomized studies have revealed important differences in these heart failure subgroups. 3, 4 Is it time to start designing trials targeting these groups separately?
Chen et al 1 used cystatin C as a clinical end point for response to therapy. Cystatin C appears to be promising as a biomarker for acute heart failure because it is less reliant on muscle mass. This is an important issue in the heart failure population, which tends to be predominantly elderly. However, more experience needs to be gained regarding its potential for evaluation as a therapeutic end point. The trial included patients with advanced renal disease and lower glomerular filtration rates than in other contemporary trials. This population might more closely reflect a real-world practice. However, it is unclear whether the advanced renal disease in itself makes such patients nonresponders to any therapeutic measure. It is important that investigators dissect these issues when designing future trials.
Sachin Kumar, MD
In Reply Dr Kumar brings up 3 relevant queries regarding the ROSE trial: (1) whether future clinical trials in acute heart failure should target heart failure with preserved ejection fraction and heart failure with reduced ejection fraction separately; (2) the relevance of cystatin C as a surrogate end point; and (3) whether the advanced renal disease in the study population makes them nonresponders to any therapeutic measure.
In the ROSE trial, there was a suggestion of differential treatment effects according to the ejection fraction in both the low-dose dopamine and low-dose nesiritide strategies. Compared with patients with reduced ejection fraction, those with heart failure and preserved ejection fraction may have experienced greater decreases in blood pressure and lesser increases in stroke volume in response to the decrease in systemic vascular resistance with low-dose dopamine or nesiritide, 1 likely due to differential ventricular vascular properties. We agree with Kumar that these findings suggest that further investigation of other acute heart failure therapies may need to assess the potential for differential responses in heart failure with preserved vs reduced ejection.
